1-2 of 2
Ingrid I.L. Berk-Planken
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B-Containing Lipoprotein and HDL in Type 2 Diabetes : A potential mechanism to lower plasma triglycerides

Free
Geesje M. Dallinga-Thie, PHD, Ingrid I.L. Berk-Planken, MD, PHD, Aart H. Bootsma, MD, PHD, Hans Jansen, PHD, on behalf of the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group
Journal: Diabetes Care
Diabetes Care 2004;27(6):1358–1364
https://doi.org/10.2337/diacare.27.6.1358
Published: 01 June 2004
View articletitled, Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B-Containing Lipoprotein and HDL in Type 2 Diabetes : A potential mechanism to lower plasma triglycerides
Open the PDF for Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B-Containing Lipoprotein and HDL in Type 2 Diabetes : A potential mechanism to lower plasma triglycerides in another window
Journal Articles

Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LIPC promoter variant

Free
Ingrid I.L. Berk-Planken, MD, Nicoline Hoogerbrugge, MD, PHD, Ronald P. Stolk, MD, PHD, Aart H. Bootsma, MD, PHD, Hans Jansen, MRBC, PHD, on behalf of the DALI study group
Journal: Diabetes Care
Diabetes Care 2003;26(2):427–432
https://doi.org/10.2337/diacare.26.2.427
Published: 01 February 2003
View articletitled, Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LIPC promoter variant
Open the PDF for Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LIPC promoter variant in another window